-
Media Release
Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
-
Media Release
Novartis Phase III study shows RLX030 improved symptoms and reduced deaths by one-third in patients with acute heart failure
-
Media Release
Novartis Phase III study shows RLX030 improved symptoms and reduced deaths by one-third in patients with acute heart failure
-
Media Release
Leeza Gibbons joins Novartis to improve caregiving experience for millions of Americans through real-world peer advice on AlzheimersDisease.com
-
Media Release
Leeza Gibbons joins Novartis to improve caregiving experience for millions of Americans through real-world peer advice on AlzheimersDisease.com
-
Media Release
Novartis Pharmaceuticals Corporation emprende una campaña de educación de la comunidad hispana de EE. UU. sobre la enfermedad de Alzheimer
-
Media Release
Novartis Pharmaceuticals Corporation embarks on Alzheimer’s disease educational effort for the U.S. Hispanic community
-
Media Release
Novartis Pharmaceuticals Corporation emprende una campaña de educación de la comunidad hispana de EE. UU. sobre la enfermedad de Alzheimer
-
Media Release
Novartis Pharmaceuticals Corporation embarks on Alzheimer’s disease educational effort for the U.S. Hispanic community
-
Media Release
FDA Advisory Committee supports use of tobramycin inhalation powder from Novartis for patients with cystic fibrosis
-
Media Release
FDA Advisory Committee supports use of tobramycin inhalation powder from Novartis for patients with cystic fibrosis
-
Media Release
Higher dose of Novartis drug Exelon® Patch approved by FDA for patients with mild to moderate Alzheimer's disease